Targeting tumor proteasome with traditional Chinese medicine

Current Drug Discovery Technologies

Volumn 7, Issue 1, 2010, Pages 46-53

  Yang, Huanjie ^a   Liu, Jinbao ^b   Dou, Q Ping ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Medicinal compounds; Natural products; Prevention; Proteasome inhibitors; Treatment

Indexed keywords

CELASTROL; F 60008; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NATURAL PRODUCT; PRISTIMERIN; PROTEASOME; TRIPTERYGIUM WILFORDII EXTRACT; TRIPTOLIDE; UBIQUITIN; UNCLASSIFIED DRUG;

ARNEBIA EUCHROMA; ARNEBIA GUTTATA; CANCER THERAPY; CELASTRUS; CELASTRUS HYPOLEUCUS; CHEMICAL STRUCTURE; CHINESE MEDICINE; CLINICAL TRIAL; CURCUMA LOGMA; CURCUMA LONGA; DENDROBIUM; DENDROBIUM LODDIGESII; DRUG TARGETING; HUMAN; LITHOSPERMUM; LITHOSPERMUM ERYTHRORHIZON; NONHUMAN; PRIORITY JOURNAL; PSORALEA; PSORALEA CORYLIFOLIA; PURPLE GROMWELL; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BENZYL COMPOUNDS; CURCUMIN; DITERPENES; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; EPOXY COMPOUNDS; HUMANS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR STRUCTURE; NAPHTHOQUINONES; NEOPLASMS; PHENANTHRENES; PHENOLS; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; TRITERPENES;

EID: 77951727526     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016310791162785     Document Type: Review

References (78)

1. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79(1): 13-21.
2. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17(24): 7151-7160 (Pubitemid 29002684)
3. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. Nature 2003; 426(6968): 895-899
4. Dou QP, Smith DM, Daniel KG, Kazi A. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy. Prog Cell Cycle Res 2003; 5: 441-446
5. Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol 2004; 5(3): 177-187
6. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin Cancer Res 2008; 14(6): 1649-1657 (Pubitemid 351469448)
7. Groll M, Ditzel L, Lowe J, et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 1997; 386(6624): 463-471 (Pubitemid 27164066)
8. Orlowski RZ, Baldwin AS, Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002; 8(8): 385-389
9. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009; 8(1): 33-40.
10. Bhoj VG, Chen ZJ. Ubiquitylation in innate and adaptive immunity. Nature 2009; 458(7237): 430-437
11. Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res 2008; 42(1-3): 3-18.
12. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, Harper JW. The SCFbeta-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha ubiquitination in vitro. Genes Dev 1999; 13(3): 270-283 (Pubitemid 29095799)
13. Biswas DK, Iglehart JD. Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer. J Cell Physiol 2006; 209(3): 645-652
14. Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007; 109(5): 2100-2105 (Pubitemid 46348211)
15. Yang H, Zonder JA, Dou QP. Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs 2009; 18(7): 957-971
16. Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: A meta-analysis. Nephron 2009; 111(4): c223-28.
17. Luo XL, Shao Q, Qu HB, Cheng YY. Simple method for determination of five terpenoids from different parts of Tripterygium wilfordii and its preparations by HPLC coupled with evaporative light scattering detection. J Sep Sci 2007; 30(9): 1284-1291 (Pubitemid 46979325)
18. Deng W. Analysis of the Toxicities and Side Effects of Leigongteng. Pharmacology and Clinics of Chinese Materia Medica 2001; 17(3): 42-47.
19. Zhou BN. Some progress on the chemistry of natural bioactive terpenoids from Chinese medicinal plants. Mem Inst Oswaldo Cruz 1991; 86(Suppl 2): 219-226
20. Kupchan SM, Schubert RM. Selective alkylation: A biomimetic reaction of the antileukemic triptolides? Science 1974; 185(153): 791-793
21. Leuenroth SJ, Crews CM. Studies on calcium dependence reveal multiple modes of action for triptolide. Chem Biol 2005; 12(12): 1259-1268
22. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002; 8(8): 2666-2674
23. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem 1999; 274(19): 13451-13455 (Pubitemid 129518558)
24. Jiang XH, Wong BC, Lin MC, et al. Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene 2001; 20(55): 8009-8018
25. Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purinebox/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274(19): 13443-13450 (Pubitemid 129518557)
26. Zhu W, Ou Y, Li Y, et al. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol 2009; 75(4): 812-819
27. Chang HJ, Kim MH, Baek MK, et al. Triptolide inhibits tumor promoter-induced uPAR expression via blocking NF-kappaB signaling in human gastric AGS cells. Anticancer Res 2007; 27(5A): 3411-3417
28. Vispe S, Devries L, Creancier L, et al. Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther 2009; 8(10): 2780-2790
29. Kitzen JJ, de Jonge MJ, Lamers CH, et al. Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur J Cancer 2009; 45(10): 1764-1772
30. Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res 2006; 66(21): 10425-10433
31. Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006; 66(9): 4758-4765
32. Lee JH, Koo TH, Yoon H, et al. Inhibition of NF-kappa B activation through targeting I kappa B kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006; 72(10): 1311-1321 (Pubitemid 44572192)
33. Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007; 109(7): 2727-2735 (Pubitemid 46482064)
34. Westerheide SD, Bosman JD, Mbadugha BN, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 2004; 279(53): 56053-56060 (Pubitemid 40066613)
35. Cullinan SB, Whitesell L. Heat shock protein 90: A unique chemotherapeutic target. Semin Oncol 2006; 33(4): 457-465 (Pubitemid 44142734)
36. Hieronymus H, Lamb J, Ross KN, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10(4): 321-330 (Pubitemid 44512193)
37. Zhang T, Hamza A, Cao X, et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008; 7(1): 162-170
38. Hughes D, Guttenplan JB, Marcus CB, Subbaramaiah K, Dannenberg AJ. Heat shock protein 90 inhibitors suppress aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and DNA adduct formation. Cancer Prev Res 2008; 1(6): 485-493
39. Huang Y, Zhou Y, Fan Y, Zhou D. Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett 2008; 264(1): 101-106
40. Luo DQ, Wang H, Tian X, Shao HJ, Liu JK. Antifungal properties of pristimerin and celastrol isolated from Celastrus hypoleucus. Pest Manag Sci 2005; 61(1): 85-90. (Pubitemid 40065151)
41. Buffa Filho W, Corsino J, Bolzani da SV, Furlan M, Pereira AM, Franca SC. Quantitative determination for cytotoxic Friedo-noroleanane derivatives from five morphological types of Maytenus ilicifolia (Celastraceae) by reverse-phase high-performance liquid chromatography. Phytochem Anal 2002; 13(2): 75-78 (Pubitemid 34285519)
42. Yang H, Landis-Piwowar KR, Lu D, et al. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem 2008; 103(1): 234-244
43. Tiedemann RE, Schmidt J, Keats JJ, et al. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood 2009; 113(17): 4027-4037
44. Wu CC, Chan ML, Chen WY, Tsai CY, Chang FR, Wu YC. Pristimerin induces caspase-dependent apoptosis in MDA-MB-231 cells via direct effects on mitochondria. Mol Cancer Ther 2005; 4(8): 1277-1285
45. Byun JY, Kim MJ, Eum DY, et al. Reactive oxygen species-dependent activation of Bax and PARP-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells. Mol Pharmacol 2009; 76(4): 734-744
46. Chen X, Yang L, Zhang N, et al. Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother 2003; 47(9): 2810-2816 (Pubitemid 37040252)
47. Chen X, Yang L, Oppenheim JJ, Howard MZ. Cellular pharmacology studies of shikonin derivatives. Phytother Res 2002; 16(3): 199-209. (Pubitemid 34534943)
48. Yang H, Zhou P, Huang H, et al. Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Intl J Cancer 2009; 124(10): 2450-2459
49. Han W, Xie J, Li L, Liu Z, Hu X. Necrostatin-1 reverts shikonin-induced necroptosis to apoptosis. Apoptosis 2009; 14(5): 674-686
50. Han W, Li L, Qiu S, et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007; 6(5): 1641-1649 (Pubitemid 46954031)
51. Zhang Y, Qian RQ, Li PP. Shikonin, an ingredient of Lithospermum erythrorhizon, down-regulates the expression of steroid sulfatase genes in breast cancer cells. Cancer Lett 2009; 284(1): 47-54.
52. Guo XP, Zhang XY, Zhang SD. Clinical trial on the effects of shikonin mixture on later stage lung cancer. Zhong Xi Yi Jie He Za Zhi 1991; 11(10): 598-99, 580.
53. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65(11): 1631-1652
54. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol Sci 2009; 30(2): 85-94.
55. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269(2): 199-225.
56. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008; 68(18): 7283-7292
57. Bharti AC, Shishodia S, Reuben JM, et al. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103(8): 3175-3184 (Pubitemid 38451696)
58. Hussain AR, Ahmed M, Al-Jomah NA, et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008; 7(10): 3318-3329
59. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 70(5): 700-713. (Pubitemid 41058705)
60. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5(1): 119-127 (Pubitemid 29045184)
61. Kang HJ, Lee SH, Price JE, Kim LS. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J 2009; 15(3): 223-229
62. Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers. Biochem Parmacol 2010; 79(2): 218-228
63. Garcea G, Jones DJ, Singh R, et al. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Br J Cancer 2004; 90(5): 1011-1015 (Pubitemid 38499692)
64. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008; 14(14): 4491-4499
65. Sharma RA, McLelland HR, Hill KA, et al. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin Cancer Res 2001; 7(7): 1894-1900 (Pubitemid 32994823)
66. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin Cancer Res 2004; 10(20): 6847-6854
67. Garcea G, Berry DP, Jones DJ, et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005; 14(1): 120-125 (Pubitemid 40165291)
68. Tang SY, Gruber J, Wong KP, Halliwell B. Psoralea corylifolia L. inhibits mitochondrial complex I and proteasome activities in SHSY5Y cells. Ann N Y Acad Sci 2007; 1100: 486-496 (Pubitemid 47092687)
69. Zhao G, Zheng XW, Qin GW, Gai Y, Jiang ZH, Guo LH. In vitro dopaminergic neuroprotective and in vivo antiparkinsonian-like effects of Delta 3,2-hydroxybakuchiol isolated from Psoralea corylifolia (L). Cell Mol Life Sci 2009; 66(9): 1617-1629
70. Ji L, Xu Z. Review of constituents in fruits of Psoralea corylifolia L. Zhongguo Zhong Yao Za Zhi 1995; 20(2): 120-22, 128.
71. Yadava RN, Verma V. A new biologically active flavonol glycoside from Psoralea corylifolia (Linn). J Asian Nat Prod Res 2005; 7(4): 671-675 (Pubitemid 40916201)
72. Chen B, Liu LL, Zhai ZX, Chen W, Fang HS, Wu YT. Determination of major components in Psoralea corylifolia L. by using supercritical fluid extraction (SFE). Se Pu 2000; 18(1): 61-63
73. Qiao CF, Han QB, Mo SF, et al. Psoralenoside and isopsoralenoside, two new benzofuran glycosides from Psoralea corylifolia. Chem Pharm Bull 2006; 54(5): 714-716.
74. Pae HO, Cho H, Oh GS, et al. Bakuchiol from Psoralea corylifolia inhibits the expression of inducible nitric oxide synthase gene via the inactivation of nuclear transcription factor-kappaB in RAW 264.7 macrophages. Int Immunopharmacol 2001; 1(9-10): 1849-1855
75. Ho CK, Chen CC. Moscatilin from the orchid Dendrobrium loddigesii is a potential anticancer agent. Cancer Invest 2003; 21(5): 729-736
76. Li MF, Hirata Y, Xu GJ, Niwa M, Wu HM. Studies on the chemical constituents of Dendrobium loddigesii rolfe. Yao Xue Xue Bao 1991; 26(4): 307-710.
77. Liu YN, Pan SL, Peng CY, et al. Moscatilin repressed lipopolysaccaride- induced HIF-1alpha accumulation and NF-kappaB activation in murine RAW264.7 cells. Shock 2009 May 18.
78. Chen TH, Pan SL, Guh JH, et al. Moscatilin induces apoptosis in human colorectal cancer cells: a crucial role of c-Jun NH2-terminal protein kinase activation caused by tubulin depolymerization and DNA damage. Clin Cancer Res 2008; 14(13): 4250-4258